Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Am J Med Genet A. 2010 Jan;152A(1):91–95. doi: 10.1002/ajmg.a.33148

Figure 1. Aberrant Behavior Checklist scores in cholesterol treated and untreated Smith-Lemli-Opitz syndrome patients.

Figure 1

A) The mean and SEM of the hyperactivity subscale scores at the start of the study (9.2 ± 2.2), after open label supplementation with 150 mg/kg cholesterol (8.4 ± 2.0), or during either of the masked phases (8.6 ± 2.3 for the placebo phase and 8.6 ± 2.2 for the supplemented phase) did not differ significantly. B) The mean and SEM of the total ABC scores at the start of the study (21.8 ± 3.5), after open label supplementation with 150 mg/kg cholesterol (20.2 ± 2.9), or during either of the masked phases (23.2 ± 4.8 for the placebo phase and 23.0 ± 3.2 for the supplemented phase) did not differ significantly.